Lupus & antiphospholipid syndrome
Development and validation of a lectin-based assay for detection of IgG Fc glycosylation as a biomarker in lupus nephritis
Authors' conclusion
The developed lectin-ELISA assay can detect glycosylation characteristics of IgG in a more cost-effective, clinically applicable manner compared with mass spectrometry.
Study context
- Population
- Systemic lupus erythematosus (SLE) cohort: patients with lupus nephritis (LN) and non-renal SLE
- Comparison
- Lectin-based ELISA (Aleuria aurantia lectin (AAL), ECL, SNA) of IgG glycosylation in active LN vs active non-renal SLE and quiescent SLE
- Outcome
- Lectin binding to IgG by SLE subgroup
Methodological detailsassay development and validation
- Assay development and validation
Performance
As reported in the abstract
- Selected lectins produced reproducible standard curves with strong linearity
- Healthy donor vs LN patient IgG: glycan differences consistent with mass spectrometry data
- AAL (fucose) binding did not differ among SLE subgroups
- ECL (galactose) binding differed significantly in active LN vs active non-renal SLE and quiescent disease
- SNA (sialic acid) binding distinguished active LN from quiescent SLE but did not discriminate renal from non-renal SLE
Original publication
Development and validation of a lectin-based assay for detection of IgG Fc glycosylation as a biomarker in lupus nephritis. Lupus Sci Med. Published 2 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →